New direct-acting antivirals have the ability to cure chronic hepatitis C virus infection, but the costs of these treatments and the number of patients that need them could bring about financial struggles for health systems.

This journal article examines Medicaid reimbursement for HCV medications in the periods before and after the aforementioned direct-acting antivirals were made available. The report also analyzes the the effect of Medicaid expansion on reimbursement for direct-acting antivirals.